Medicamentos genéricos no tratamento das epilepsias: uma reflexão

• Autor(a) principal: Yacubian, Elza Márcia Targas [UNIFESP]
• Data de Publicação: 2007
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S1676-26492007000300007; http://repositorio.unifesp.br/handle/11600/3922
• topic: generics; bioequivalence; bioavailability; interchangeability; medicamentos genéricos; bioquivalência; biodisponibilidade; intercambialidade

OBJECTIVE: We discuss some controversial aspects with prescription of generic drugs (GD) and the problems concerning bioequivalence in the treatment of epilepsy. Some antiepileptic drugs (AED) are poorly soluble in water, have nonlinear kinetics and a narrow therapeutic range, implying that problems with bioequivalence are likely to occur. There are clearly advantages (cost saving) and disadvantages (loss of seizure control or drug toxicity) in prescribing generics AED. METHODS: Review of literature. RESULTS AND CONCLUSION: The main information is about classical AED (phenytoin, carbamazepine and valproate). Regarding the new AED we found only one poster presentation related to lamotrigine substitution. The level of evidence is, generally, weak, based on case-series and expert opinion without explicit critical appraisal (except in phenytoin with level of evidence moderate, based on some analytical studies). We may allow the use of generics for epilepsy treatment. However, this opens the possibility of successive substitution of different formulations which may even be life threatening.